Antiendotoxin strategies (Q77787045)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10340172%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

title

Antiendotoxin strategies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10340172%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

J Hellman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10340172%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

H S Warren

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10340172%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

publication date

1 June 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10340172%20AND%20SRC:MED&resulttype=core&format=json

Infectious Disease Clinics of North America

8 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10340172%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10340172%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10340172%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

page(s)

371-86, ix

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10340172%20AND%20SRC:MED&resulttype=core&format=json

Biochemical characterization of recombinant fusions of lipopolysaccharide binding protein and bactericidal/permeability-increasing protein. Implications in biological activity

8 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

An analogue of lipid A and LPS from Rhodobacter sphaeroides inhibits neutrophil responses to LPS by blocking receptor recognition of LPS and by depleting LPS-binding protein in plasma.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Limulus antilipopolysaccharide factor protects rabbits from meningococcal endotoxin shock.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: a prospective, double-blind, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

A phase I safety and pharmacokinetic study of a recombinant amino terminal fragment of bactericidal/permeability-increasing protein in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Affinity-purified Escherichia coli J5 lipopolysaccharide-specific IgG protects neutropenic rats against gram-negative bacterial sepsis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against gram-negative bacteremia.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Therapeutic efficacy of a polymyxin B-dextran 70 conjugate in experimental model of endotoxemia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Detoxification of plasma containing lipopolysaccharide by adsorption.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

E5531, a pure endotoxin antagonist of high potency

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Bactericidal/permeability-increasing protein inhibits induction of macrophage nitric oxide production by lipopolysaccharide

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

hCAP-18, a cathelin/pro-bactenecin-like protein of human neutrophil specific granules

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Antiendotoxin antibodies: a dead end?

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Polymyxin-dextran antiendotoxin pretreatment in an ovine model of normotensive sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Covalent Polymyxin B Conjugate with Human Immunoglobulin G as an Antiendotoxin Reagent

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

The bactericidal/permeability-increasing protein (BPI), a potent element in host-defense against gram-negative bacteria and lipopolysaccharide.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Bactericidal/permeability increasing protein and host defense against gram-negative bacteria and endotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Human neutrophil bactericidal/permeability-increasing protein reduces mortality rate from endotoxin challenge: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

A novel peptide-IgG conjugate, CAP18(106-138)-IgG, that binds and neutralizes endotoxin and kills gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Polymyxin B moderates acidosis and hypotension in established, experimental gram-negative septicemia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Analysis of LPS released from Salmonella abortus equi in human serum

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Effect of a recombinant endotoxin-neutralizing protein on endotoxin shock in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Relationship of Tissue and Cellular Interleukin‐1 and Lipopolysaccharide after Endotoxemia and Bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Cellular distribution of endotoxin after injection of chemically purified lipopolysaccharide differs from that after injection of live bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Lipid X protects mice against fatal Escherichia coli infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Lipid X ameliorates pulmonary hypertension and protects sheep from death due to endotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Antiserum againstEscherichia coliJ5 Contains Antibodies Reactive with Outer Membrane Proteins of Heterologous Gram‐Negative Bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Antibodies to Core Lipopolysaccharide Determinants: Absence of Cross-reactivity with Heterologous Lipopolysaccharides

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Competition between bactericidal/permeability-increasing protein and lipopolysaccharide-binding protein for lipopolysaccharide binding to monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Blood purification for prevention and treatment of multiple organ failure

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Crystal structure of an endotoxin-neutralizing protein from the horseshoe crab, Limulus anti-LPS factor, at 1.5 A resolution.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Extracorporeal adsorbent-based strategies in sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Immunization with rough mutants of Salmonella minnesota. IV. Protection by antisera to O and rough antigens against endotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Functional activities of monoclonal antibodies to the O side chain of Escherichia coli lipopolysaccharides in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Enzymatically deacylated lipopolysaccharide (LPS) can antagonize LPS at multiple sites in the LPS recognition pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Synthetic peptides that mimic the binding site of horseshoe crab antilipopolysaccharide factor

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Human monocyte CD14 is upregulated by lipopolysaccharide.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Increased Circulating Soluble Cd14 Is Associated With High Mortality In Gram-Negative Septic Shock

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Antibodies against CD14 protect primates from endotoxin-induced shock

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

In vivo protection against endotoxin by plasma high density lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Extracorporeal endotoxin removal in a canine model of septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Lipopolysaccharide antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Neither CD14 nor serum is absolutely necessary for activation of mononuclear phagocytes by bacterial lipopolysaccharide

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Cross-Reactive Antigens: Their Potential for Immunization-Induced Immunity to Gram-Negative Bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Immunization with rough mutants of Salmonella minnesota: protective activity of IgM and IgG antibody to the R595 (Re chemotype) mutant

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Type-Specific and Cross-Reactive Antibodies in Gram-Negative Bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Isolation and biological activities of limulus anticoagulant (anti-LPS factor) which interacts with lipopolysaccharide (LPS).

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Biological activity, lipoprotein-binding behavior, and in vivo disposition of extracted and native forms of Salmonella typhimurium lipopolysaccharides

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Primary structure of anti-lipopolysaccharide factor from American horseshoe crab, Limulus polyphemus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Recombinant endotoxin neutralizing protein improves survival from Escherichia coli sepsis in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Endotoxin-neutralizing properties of the 25 kD N-terminal fragment and a newly isolated 30 kD C-terminal fragment of the 55-60 kD bactericidal/permeability-increasing protein of human neutrophils.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Relative concentrations of endotoxin-binding proteins in body fluids during infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Plasma lipopolysaccharide-binding protein is found associated with a particle containing apolipoprotein A-I, phospholipid, and factor H-related proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole blood

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Triglyceride-rich lipoproteins prevent septic death in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Anti-endotoxin therapy in primate bacteremia with HA-1A and BPI.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

The role of bactericidal/permeability-increasing protein in the treatment of primate bacteremia and septic shock.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

LimulusAntilipopolysaccharide Factor Prevents Mortality Late in the Course of Endotoxemia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Pulmonary and hepatic gene expression following cecal ligation and puncture: monophosphoryl lipid A prophylaxis attenuates sepsis-induced cytokine and chemokine expression and neutrophil infiltration

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Estimation of protective levels of anti-O-specific lipopolysaccharide immunoglobulin G antibody against experimental Escherichia coli infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Structure and function of lipopolysaccharide binding protein

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

A comparison of bactericidal/permeability-increasing protein variant versus recombinant endotoxin-neutralizing protein for the treatment of Escherichia coli sepsis in rats .

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Protection against lethality of E. coli endotoxin with "O" antiserum

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Lipopolysaccharide binding protein-mediated complexation of lipopolysaccharide with soluble CD14.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Lipopolysaccharide (LPS)-binding proteins BPI and LBP form different types of complexes with LPS.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

The modification of biophysical and endotoxic properties of bacterial lipopolysaccharides by serum

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

New function for high density lipoproteins. Their participation in intravascular reactions of bacterial lipopolysaccharides

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

New function for high density lipoproteins. Isolation and characterization of a bacterial lipopolysaccharide-high density lipoprotein complex formed in rabbit plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Effect of hypertriglyceridemia on endotoxin responsiveness in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

The role of lipoproteins and receptor-mediated endocytosis in the transport of bacterial lipopolysaccharide

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Protective effects of a novel 32-amino acid C-terminal fragment of CAP18 in endotoxemic pigs.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Binding and neutralization of endotoxin by Limulus antilipopolysaccharide factor

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Binding and neutralization of bacterial lipopolysaccharide by colistin nonapeptide

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Human bactericidal/permeability-increasing protein and a recombinant NH2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Cathelicidins: a novel protein family with a common proregion and a variable C‐terminal antimicrobial domain

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970080-5

7 January 2021

10.1016/S0891-5520(05)70080-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10340172%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10340172%20AND%20SRC:MED&resulttype=core&format=json